Mechanisms of immune evasion by tumors.
By Charles G. Drake, E. Jaffee, D. Pardoll. Advances in Immunology, 2006
690 citations recorded by the source corpus.
Subfields: Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/36bd3966efbdb1ac1cf5340241d080be580bd8ff
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
- J. Wolchok
- Lieping Chen
- D. Gabrilovich
- Yiping Yang
- D. Pardoll
- Gabriel A. Rabinovich
- I. Melero
- E. Sotomayor
In Oncology
- J. Wolchok
- Lieping Chen
- D. Pardoll
- Yiping Yang
- Gabriel A. Rabinovich
- D. Gabrilovich
- Timothy A. Chan
- I. Melero
Citations in the corpus
- Immunostimulatory monoclonal antibodies for cancer therapy (2007, background): “As such they have the potential to increase the immune response to tumours, which is suppressed in many cancer patients through various mechanism”
- Cancer immunotherapy: the beginning of the end of cancer? (2016, background): “Although an endogenous immune response to cancer is observed in preclinical models and patients, this response is not efficient because tumors induce tolerance among tumor-specific T cells and by expressing ligands that bind inhibitory receptors and dampen T cell functions within the tumor microenvi”
- Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses (2015, positive): “We hypothesize the low group may represent an ‘‘immune evasion/immune editing’’ pattern (Drake et al., 2006; Schreiber et al., 2011) that Aza could reverse to sensitize patients to subsequent immune therapy (Li et al., 2014).”
- Immunosuppressive strategies that are mediated by tumor cells. (2007, background): “These include alterations of components of the antigen presentation machinery, defects in proximal TCR signaling, secretion of immunosuppressive and proapoptotic factors, activation of negative regulatory pathways and specific recruitment of regulatory cell populations (2,27,52,53) (Fig.”
- Cancer immunotherapy: harnessing the immune system to battle cancer. (2015, background): “This limited efficacy is due to the ability of tumor cells to avoid recognition and elimination by the immune system, allowing them to become established in the host (1).”